ClearPoint Neuro Q2 revenue rises 18% but misses estimates

Clearpoint Neuro

03/08/2026 21:14

Overview
Device and gene therapy-enabling firm's Q2 revenue rose 18% yr/yr but missed analyst expectations
Gross margin improved to 62% from 60% a year ago
Company cut 2026 revenue guidance to $48-52 mln, citing shift to clinical support and product development

Outlook
ClearPoint Neuro sees 2026 revenue between $48 mln and $52 mln
Company expects 10-15 clinical trials using its technology to be enrolling in next 18 months
Company expects first GLP preclinical services project at CAL to complete in H1 2027

Result Drivers
BIOLOGICS AND DRUG DELIVERY DECLINE - Co said segment revenue fell 15% due to lower product shipments for new biopharma trial initiations, partially offset by growth in preclinical service revenue
NEUROSURGERY NAVIGATION GROWTH - Neurosurgery navigation and therapy revenue rose 62%, driven by IRRAflow product sales and new navigation software, which boosted procedural volumes
OPERATING EXPENSES RISE - Operating expenses rose 51% mainly due to the IRRAS acquisition, higher personnel costs, and increased occupancy and travel costs

Company press release: ID:nACSBT1NNa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$10.90 mln
$12.73 mln (3 Analysts)
Q2 Gross Margin
 
62.00%
 
Q2 Operating Expenses
 
$17 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Clearpoint Neuro Inc is $30.00, about 100.8% above its July 31 closing price of $14.94

Reuters Recommended Reads
Aug 3 - Curium strikes up to $8 bln deal for radiopharma peer Lantheus
Aug 3 - Latigo, BlossomHill launch US IPOs as biotech listings rebound
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)